Notice of Allowability	Application No.	Applicant(s)
	10/629,858	CARTER, DANIEL C.
	Examiner	Art Unit
	Bernard Dentz	1625
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <i>Rule 132 Declaration of 8-22-2006</i> .		
2. The allowed claim(s) is/are <u>1-7</u> .		
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some* c) None of the:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.  5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.  (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached  1) hereto or 2) to Paper No./Mail Date  (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).  6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)  1. ☑ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. ☐ Notice of Informal F 6. ☐ Interview Summary Paper No./Mail Da 7. ☒ Examiner's Amend 8. ☒ Examiner's Statem 9. ☐ Other	/ (PTO-413), ate
II S. Potent and Trademed Office		

i.e

Application/Control Number: 10/629,858

Art Unit: 1625

The Drawings filed 7-30-2003 have been accepted.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Non-elected claims 8-10 have been canceled without prejudice.

The following is an examiner's statement of reasons for allowance: A

Declaration under Rule 132 was filed by Dr. Michael Kirkup, Ph.D. It seeks to overcome
the lack of enablement rejection. The Examiner has contended that one of ordinary skill
in the art could not without undue experimentation synthesize the instantly claimed
novel analogs of Warfarin.

In the Declaration Kirkup stated that he was asked by applicant's assignee to prepare these compounds. He states that he was readily able to prepare these compounds using a variety of techniques available to him or any other practitioner skilled in this art and that the processes used to prepare these specific compounds were adapted from conventional synthetic reactions, many of which had been disclosed in journal references.

The Declarant then goes on to cite these references, which have now been made of record, and also gives the exact chemical protocol that he and his colleagues used to make the compounds.

Application/Control Number: 10/629,858

Art Unit: 1625

On examination of these references along with US Patent 2,427,578, which is incorporated by reference on p. 2 of the instant specification, the Examiner has withdrawn the lack of enablement rejection.

This is because the cited references disclose the modification of the standard general synthesis first disclosed in said US Patent 2,427,578 in the synthesis of different Warfarin analogs. The modification is the selecting of the alpha, beta-unsaturated ketone reactant depending on the particular Warfarin analog intended.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is 571-272-0683. The examiner can normally be reached on Mon-Fri from 8 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thomas McKenzie, can be reached on 571 272-0670. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

Art Unit: 1625

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Dentz

10-5-2006

BERNAHD DENTZ PRIMARY EXAMINER